Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ‘eye stroke’ (ischaemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an… read more.
Tenpoint Therapeutics, Ltd., announced that the FDA approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop… read more.
Real-world data show that intravitreal fluocinolone implants can improve visual acuity and reduce the need for systemic treatment in patients with uveitis. In this interview Ann Marie Goacher,… read more.
The European Commission has granted marketing authorization in the European Union (EU) for Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the treatment of… read more.
A new study from UCLA Health shows that a cardiovascular risk score already used routinely in primary care can predict who will develop serious eye diseases years later…. read more.
In the common vision disorder amblyopia, impaired vision in one eye during development causes neural connections in the brain’s visual system to shift toward supporting the other eye,… read more.
Clinical Pharmacy Congress North – Congress highlights A drug-eluting implant has been shown to reverse cystoid macular oedema and reduce the need for systemic treatment in 80% of… read more.
The world’s largest collection of curated eye imaging and linked clinical data is expanding across the country, in an initiative led out of Moorfields Eye Hospital NHS Foundation… read more.
GERPAC Congress highlights Cyclodextrin-based chlorhexidine eye drops represent a promising approach to formulating stable and effective treatments for Acanthamoeba keratitis, according to researchers from the University of Picardy… read more.
GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting… read more.
NICE (UK): Idebenone is recommended, within its marketing authorisation, as an option for treating visual impairment in Leber’s hereditary optic neuropathy (LHON) in people 12 years and over…. read more.
Alvotech and Advanz Pharma announced that the European Commission has approved Mynzepli as a biosimilar to Eylea (aflibercept), in a pre-filled syringe and vial. The centralized marketing authorization… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
